EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access

Gene Editing for CEP290 -Associated Retinal Degeneration

Eric A Pierce, Tomas S Aleman, Kanishka T Jayasundera, Bright S Ashimatey, Keunpyo Kim iD, Alia Rashid, Michael C Jaskolka iD, Rene L Myers, Byron L Lam, Steven T Bailey, Jason I Comander, Andreas K Lauer und 2 weitere

New England Journal of Medicine · 06.06.2024 · 390 (21) · 1972-1984

DOI: 10.1056/nejmoa2309915 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 06.06.2024. Verfasst von Eric A Pierce und 13 weiteren Autor:innen. Beteiligte Einrichtung: From the Ocular Genomics Institute, Department of Ophthalmology, Mass Eye and Ear and Harvard Medical School, Boston (E.A.P., J.I.C.), and Editas Med…. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Cell Cycle Proteins, Cytoskeletal Proteins, Gene Editing. Die Arbeit wurde bisher 232-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, Malcolm M. Marquis MD Endowed Fund for Innovation, Research to Prevent Blindness.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmCell Cycle ProteinsCytoskeletal ProteinsGene EditingRetinal DegenerationAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultCRISPR-Cas SystemsGenetic TherapyInjections, IntraocularQuality of LifeRetinaVisual Acuity

Substanzen

Antigens, NeoplasmCell Cycle ProteinsCep290 protein, humanCytoskeletal Proteins

Autor:innen und Institutionen

  • From the Ocular Genomics Institute, Department of Ophthalmology, Mass Eye and Ear and Harvard Medical School, Boston (E.A.P., J.I.C.), and Editas Medicine, Cambridge (B.S.A., K.K., A.R., M.C.J., R.L.M.) - both in Massac…

ORCID-Profile: Keunpyo Kim, Michael C Jaskolka

Förderung

  • NEI NIH HHS
  • Malcolm M. Marquis MD Endowed Fund for Innovation
  • Research to Prevent Blindness
  • Irene Heinz Given and John La Porte Given Endowment
  • Hope For Vision
  • National Eye Institute
  • Editas Medicine

Zitieren

APA

Pierce, E. A., Aleman, T. S., Jayasundera, K. T., Ashimatey, B. S., Kim, K., Rashid, A., Jaskolka, M. C., Myers, R. L., Lam, B. L., Bailey, S. T., Comander, J. I., Lauer, A. K., Maguire, A. M., & Pennesi, M. E. (2024). Gene Editing for CEP290 -Associated Retinal Degeneration. New England Journal of Medicine, 390(21), 1972-1984. https://doi.org/10.1056/nejmoa2309915

Vancouver

Pierce EA, Aleman TS, Jayasundera KT, Ashimatey BS, Kim K, Rashid A, et al. Gene Editing for CEP290 -Associated Retinal Degeneration. New England Journal of Medicine. 2024;390(21):1972-1984. doi:10.1056/nejmoa2309915

BibTeX
@article{Pierce2024,
  author = {Pierce, Eric A and Aleman, Tomas S and Jayasundera, Kanishka T and Ashimatey, Bright S and Kim, Keunpyo and Rashid, Alia and Jaskolka, Michael C and Myers, Rene L and Lam, Byron L and Bailey, Steven T and Comander, Jason I and Lauer, Andreas K and Maguire, Albert M and Pennesi, Mark E},
  title = {Gene Editing for CEP290 -Associated Retinal Degeneration},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {21},
  pages = {1972--1984},
  doi = {10.1056/nejmoa2309915}
}
Kostenlos starten →